Stock Ticker

  • Loading stock data...

Isis Pharmaceuticals to Present at Credit Suisse Healthcare Conference (ISIS)

Isis Pharmaceuticals (NASDAQ: ISIS) has announced that it will be presenting an overview at the 2012 Credit Suisse Healthcare Conference on November 15. Isis, a prominent player in antisense therapeutics, saw its share prices increase by 14.6% to $8.79 after the announcement on Friday. In all, over 4 million shares changed hands during Friday’s trading session. […]

Cymer Buyout by ASML Investigated by Securities Attorneys (CYMI)

The much-awaited buyout of Cymer (NASDAQ: CYMI) by global provider of lithography systems for the semiconductor industry, ASML (NSDAQ: ASML), will be underway even though securities attorneys at The Briscoe Law Firm and Powers Taylor will be investigating the proposed buyout. The definitive merger agreement between Cymer and ASML is being valued at a little […]

Atmel Announces Release of maXTouch In-Car Control System (ATML)

Atmel (NASDAQ: ATML) has just announced the release of new automotive-qualified maXTouch controllers for small automotive touchscreens and touchpads. These new controllers can also be used as car control systems. Offering a smartphone-like experience, the maXTouch in-car control systems are perfect for contemporary cars. Even drivers who regularly wear gloves while driving will have no […]

Egyptians Revere Isis, Investors Not So Much (ISIS)

Shares of Isis Pharmaceuticals (NASDAQ: ISIS) fell off the proverbial cliff today as shares plummeted to $10.27, a loss of $2.88 per share or 21.9% percent. The reason for the loss was one-fold as the United States Food and Drug Administration expressed a number of concerns regarding the company’s key drug, Kynamro. The FDA expressed […]

Growth Side Effects Diminish Investor Value (ISIS)

Growth may be good for a developing basketball player, but US regulators do not like to see it occur in developing drug treatments. The Food and Drug Administration (FDA) rang alarm bells over a drug, Kynamro, produced by Isis Pharmaceuticals (NASDAQ: ISIS) and Sanofi (NYSE: SNY) when neoplasms developed in conjunction with the drug’s use […]

Sign Up To Get Our Latest Stocks Alerts